Edition:
United States

Amicus Therapeutics says U.S. FDA granted orphan drug designation to ATB200/AT2221 for Pompe disease


Thursday, 21 Sep 2017 07:30am EDT 

Sept 21 (Reuters) - Amicus Therapeutics Inc :Says ‍U.S. FDA has granted orphan drug designation to ATB200/AT2221​ for Pompe disease​.Amicus Therapeutics - ‍look forward to announcing new clinical data in all patients from ATB200/AT2221​ study at World Muscle Society in early Oct.